Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

SECRETARY OF THE SENATE
04 AUG 12 AM 11:52

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required to Complete This Page**

1. Registrant Name
CONGRESSIONAL CONSULTANTS

2. Address ☐ Check if different than previously reported
444 NORTH CAPITOL STREET NW, #532

3. Principal Place of Business (if different from line 2)
WASHINGTON (City:) DC 20001 (State/zip (or Country))

4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
GWEN GAMPEL PAULSON	(202) 544-6264	CCGAMPEL@SSO.ORG	10456-164

7. Client Name ☐ Self
WATSON PHARMACEUTICALS

6. House ID #
32666012

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☑ **OR** Year End (July 1-De

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☑ ⇨ Termination Date June 30, 2004 11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☑

$10,000 or more ☐ ⇨ $ _____
Income (nearest $20,000)

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this repc period were:

Less than $10,000 ☑

$10,000 or more ☐ ⇨ $ _____
Expenses (nearest $20,0(

14. REPORTING METHOD. Check box to indicate e accounting method. See instructions for description of (

☑ **Method A.** Reporting amounts using LDA definit

☐ **Method B.** Reporting amounts under section 603 Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162 Internal Revenue Code

Signature _____ Date 8/10/04

Signature _____ Date _____

Printed Name and Title GWEN GAMPEL PAULSON, President

LD-2 (REV. 4/03)

Registrant Name CONGRESSIONAL CONSULTANTS Client Name WATSON PHARMACEUTICALS

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each c** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

MEDICARE LEGISLATION AND REGULATION AFFECTING DIALYSIS PHARMACEUTICALS

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. HOUSE
U.S. SENATE
CENTERS FOR MEDICARE AND MEDICAID SERVICES

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
GWEN GAMPEL PAULSON	N/A
ALEXANDER ALONSO	N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above ☑ Check if None

Signature [signature] Date 8/10/04

GWEN GAMPEL PAULSON President

Printed Name and Title GWEN GAMPEL PAULSON, President